报价延迟最少15分钟:2025/07/20 13:16 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.52 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.17/-1.69
|
|
企业价值
22.88M
|
| 资产负债 |
|
每股账面净值
-1.08
|
| 现金流量 |
|
现金流量率
0.31
|
| 损益表 |
|
收益
9.78K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:16 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatmentof bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health. |
